Zosano Pharma to Present Phase 3 Safety Study Update for ADAM™ Technology in the Delivery of Zolmitriptan at the 5th Annual...
September 06 2018 - 8:30AM
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
“Company”), a clinical-stage biopharmaceutical company, developing
and commercializing therapies that deliver rapid systemic
absorption by leveraging its novel and proprietary technology
called Adhesive Dermally-Applied Microarray (“ADAM™”), is scheduled
to present an update on its ongoing Phase 3 long-term safety trial
utilizing its proprietary ADAM technology for the delivery of
zolmitriptan at the 5th Annual Transdermal & Intradermal Drug
Delivery Systems Conference being held on September 6-7, 2018 in
Philadelphia, PA.
“Our ADAM technology continues to perform well in clinical
studies, which supports the potential to develop ADAM with new
drugs for additional indications. One of the major potential
advantages of our ADAM technology is the ability to effectively
deliver a drug through the skin, as some drugs have poor oral
bioavailability and slow intestinal absorption," said Dr. Donald
Kellerman, vice president of clinical development and medical
affairs at Zosano. "We are pleased with these promising results and
believe that this presentation highlights the potential of our
technology for the delivery of zolmitriptan for the treatment of
migraine.”
Oral Presentation:
Update on a
Long-Term Safety Trial Using a Microneedle
SystemPresenter:
Donald Kellerman,
vice president of clinical development and medical
affairsDate:
September 7th, 2018 Time:
10:15 AM
EDTLocation:
The Racquet
Club of Philadelphia About M207M207 is our
proprietary formulation of zolmitriptan delivered utilizing
Zosano's proprietary ADAM technology. Zosano's ADAM technology
consists of titanium microprojections (microneedles) coated with
drug, and in the case of M207, our formulation of
zolmitriptan. The drug-coated microneedles penetrate
into the epidermis and dermis, where the drug is dissolved and
enters into the bloodstream. In February 2017, the Company
announced statistically significant results from the ZOTRIP pivotal
study, which demonstrated that the 3.8mg dose of M207 met both
co-primary endpoints, achieving pain freedom and most bothersome
symptom freedom at 2 hours. In November 2017, the
Company announced the initiation of its long-term safety study
evaluating M207 and expects to file an NDA for M207 in the fourth
quarter of 2019.
Forward-Looking StatementsThis press release
contains forward-looking statements regarding the timing of
expected clinical development milestones, sufficiency of our
capital resources and need for future funding and other future
events and expectations. Readers are urged to consider statements
that include the words "may," "will," "would," "could," "should,"
"might," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," "unaudited," "approximately" or the
negative of those words or other comparable words to be uncertain
and forward-looking. These statements are subject to risks and
uncertainties that are difficult to predict and actual outcomes may
differ materially. These include risks and uncertainties, without
limitation, associated with the process of discovering, developing
and commercializing products that are safe and effective for use as
human therapeutics, risks inherent in the effort to build a
business around such products and other risks and uncertainties
described under the heading "Risk Factors" in the Company's most
recent annual report on Form 10-K. Although we believe that the
expectations reflected in these forward-looking statements are
reasonable, we cannot in any way guarantee that the future results,
level of activity, performance or events and circumstances
reflected in forward-looking statements will be achieved or occur.
All forward-looking statements are based on information currently
available to Zosano and Zosano assumes no obligation to update any
such forward-looking statements.
Zosano Contact: John Walker Chief Executive
Officer and Chairman of the Board 510-745-1200
Media Contact:Sara ZelkovicLifeSci Public
Relationssara@lifescipublicrelations.com(646) 876-4933
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Sep 2023 to Sep 2024